ORBi: Detailled Reference

No full text

Article (Scientific journals)

Corticosteroids: still at the frontline in asthma treatment?

LOUIS, Renaud; SCHLEICH, FLorence; Barnes, Peter J.

2012 • In Clinics in Chest Medicine, 33 (3), p. 531-41

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/134460

DOI
10.1016/j.ccm.2012.05.004

PubMed
22929100

Files (2)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Full Text Parts

Corticosteroids_still at the frontline in asthma treatment_Louis_12_ClinChestMed.pdf

Publisher postprint (326.19 kB)

Corticosteroids_still at the frontline in asthma treatment_Louis_12_ClinChestMed.pdf

Author postprint (311.64 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Inhaled corticosteroids (ICS) have led to improved asthma control and reduced asthma mortality in the Western world. ICS are effective in combating T-helper type 2-driven inflammation featuring mast cell and eosinophilic airway infiltration. Their effect on innate immunity-driven neutrophilic inflammation is poor and their ability to prevent airway remodeling and accelerated lung decline is controversial. Although ICS remain pivotal drugs in asthma management, research is needed to find drugs complementary to the combination ICS/long-acting beta2-agonist in refractory asthma and perhaps a new class of drugs as a first-line treatment in mild to moderate noneosinophilic asthma.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

SCHLEICH, FLorence

Barnes, Peter J.

Language :

English

Title :

Corticosteroids: still at the frontline in asthma treatment?

Publication date :

2012

Journal title :

Clinics in Chest Medicine

ISSN :

0272-5231

Publisher :

W. B. Saunders Co., United Kingdom

Volume :

33

Issue :

3

Pages :

531-41

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://chestmed.theclinics.com/issues

Commentary :

Copyright (c) 2012 Elsevier Inc. All rights reserved.

Available on ORBi :

since 20 November 2012

Statistics

Number of views

253 (24 by ULiège)

Number of downloads

423 (6 by ULiège)

More statistics

Scopus citations^®

40

Scopus citations^®
without self-citations

28

OpenCitations

27

OpenAlex citations

40

Bibliography

Barnes P.J. Will it be steroids for ever?. Clin Exp Allergy 2005, 35:843-845.
Global strategy for asthma management and prevention: NHLBI/WHO workshop report March 1993 2002, National Institutes of Health, Publication number 95-36-59 issued January 1995.
Drazen J.M., Silverman E.K., Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000, 56:1054-1070.
Brown H.M., Storey G., George W.H. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972, 1:585-590.
Gaddie J., Petrie G.R., Reid I.W., et al. Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. Lancet 1973, 2:280-281.
Kriz R.J., Chmelik F., doPico G., et al. A short-term double-blind trial of aerosol triamcinolone acetonide in steroid-dependent patients with severe asthma. Chest 1976, 69:455-460.
Gerdtham U.G., Hertzman P., Jonsson B., et al. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care 1996, 34:1188-1198.
Blais L., Ernst P., Boivin J.F., et al. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998, 158:126-132.
Suissa S., Ernst P., Benayoun S., et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 343:332-336.
Haahtela T., Jarvinen M., Kava T., et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991, 325:388-392.
Djukanovic R., Roche W.R., Wilson J.W., et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990, 142:434-457.
Kay A.B. Allergy and allergic diseases. First of two parts. N Engl J Med 2001, 344:30-37.
Corrigan C. The eotaxins in asthma and allergic inflammation: implications for therapy. Curr Opin Investig Drugs 2000, 1:321-328.
Djukanovic R., Wilson J.W., Britten K.M., et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992, 145:669-674.
Laitinen L.A., Laitinen A., Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992, 90:32-42.
Aldridge R.E., Hancox R.J., Robin T.D., et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000, 161:1459-1464.
Fahy J.V., Boushey H.A. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. Eur Respir J 1998, 11:1240-1247.
Jatakanon A., Lim S., Chung K.F., et al. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J 1998, 12:1084-1088.
van Rensen E.L., Straathof K.C., Veselic-Charvat M.A., et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999, 54:403-408.
Meijer R.J., Kerstjens H.A., Arends L.R., et al. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax 1999, 54:894-899.
Corrigan C.J., Haczku A., Gemou-Engesaeth V., et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis 1993, 147:540-547.
Lilly C.M., Nakamura H., Kesselman H., et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997, 99:1767-1773.
Maneechotesuwan K., Yao X., Ito K., et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009, 6:e1000076.
Pauwels R.A., Pedersen S., Busse W.W., et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003, 361:1071-1076.
Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
James A.L., Palmer L.J., Kicic E., et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005, 171:109-114.
Lange P., Parner J., Vestbo J., et al. 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998, 339:1194-1200.
O'Byrne P.M., Pedersen S., Busse W.W., et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006, 129:1478-1485.
Sont J.K., Willems L.N., Bel E.H., et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999, 159:1043-1051.
Ward C., Pais M., Bish R., et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002, 57:309-316.
Cokugras H., Akcakaya N., Seckin I., et al. Ultrastructural examination of bronchial biopsy specimens from children with moderate asthma. Thorax 2001, 56:25-29.
Jenkins H.A., Cool C., Szefler S.J., et al. Histopathology of severe childhood asthma: a case series. Chest 2003, 124:32-41.
Davies D.E., Wicks J., Powell R.M., et al. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003, 111:215-225.
Grainge C.L., Lau L.C., Ward J.A., et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011, 364:2006-2015.
Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004, 170:836-844.
Antonicelli L., Bucca C., Neri M., et al. Asthma severity and medical resource utilisation. Eur Respir J 2004, 23:723-729.
Barnes P.J., Jonsson B., Klim J.B. The costs of asthma. Eur Respir J 1996, 9:636-642.
Godard P., Chanez P., Siraudin L., et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002, 19:61-67.
Serra-Batlles J., Plaza V., Morejon E., et al. Costs of asthma according to the degree of severity. Eur Respir J 1998, 12:1322-1326.
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000, 162:2341-2351.
Chanez P., Wenzel S.E., Anderson G.P., et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007, 119:1337-1348.
Jatakanon A., Uasuf C., Maziak W., et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999, 160:1532-1539.
Louis R., Lau L.C., Bron A.O., et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000, 161:9-16.
Wenzel S.E., Schwartz L.B., Langmack E.L., et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-1008.
ten Brinke A., Grootendorst D.C., Schmidt J.T., et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002, 109:621-626.
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003, 22:470-477.
ten Brinke A., Zwinderman A.H., Sterk P.J., et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170:601-605.
Green R.H., Brightling C.E., McKenna S., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-1721.
Jayaram L., Pizzichini M.M., Cook R.J., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006, 27:483-494.
Duncan C.J., Lawrie A., Blaylock M.G., et al. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 2003, 22:484-490.
Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
Baraniuk J.N., Ali M., Brody D., et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997, 155:704-710.
Mak J.C., Nishikawa M., Barnes P.J. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995, 268:L41-L46.
Roth M., Johnson P.R., Rudiger J.J., et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002, 360:1293-1299.
Thomson N.C., Spears M. The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol 2005, 5:57-63.
Barnes P.J. Reduced histone deacetylase in COPD: clinical implications. Chest 2006, 129:151-155.
Hew M., Bhavsar P., Torrego A., et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006, 174:134-141.
Ito K., Ito M., Elliott W.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352:1967-1976.
Irusen E., Matthews J.G., Takahashi A., et al. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109:649-657.
Matthews J.G., Ito K., Barnes P.J., et al. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004, 113:1100-1108.
Goleva E., Li L.B., Eves P.T., et al. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006, 173:607-616.
Pujols L., Mullol J., Picado C. Alpha and beta glucocorticoid receptors: relevance in airway diseases. Curr Allergy Asthma Rep 2007, 7:93-99.
Alcorn J.F., Crowe C.R., Kolls J.K. TH17 cells in asthma and COPD. Annu Rev Physiol 2010, 72:495-516.
McKinley L., Alcorn J.F., Peterson A., et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008, 181:4089-4097.
Peters S.P., Kunselman S.J., Icitovic N., et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363:1715-1726.
Hanania N.A., Alpan O., Hamilos D.L., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
Humbert M., Beasley R., Ayres J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
Louis R. Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases. Allergy 2004, 59:698-700.
Djukanovic R., Wilson S.J., Kraft M., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170:583-593.
van Rensen E.L., Evertse C.E., van Schadewijk W.A., et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009, 64:72-80.
Wu A.C., Paltiel A.D., Kuntz K.M., et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007, 120:1146-1152.
Manise M., Schleich F., Gusbin N., et al. Cytokine production from sputum cells and blood leukocytes in asthmatics according to disease severity. Allergy 2010, 65:889-896.
Cho S.H., Stanciu L.A., Holgate S.T., et al. Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma. Am J Respir Crit Care Med 2005, 171:224-230.
Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
Kips J.C., O'Connor B.J., Langley S.J., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659.
Leckie M.J., ten Brinke A., Khan J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
Castro M., Mathur S., Hargreave F., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132.
Berry M.A., Hargadon B., Shelley M., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697-708.
Howarth P.H., Babu K.S., Arshad H.S., et al. Tumour necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012-1018.
Morjaria J.B., Chauhan A.J., Babu K.S., et al. The role of a soluble TNF alpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008, 63:584-591.
Erin E.M., Leaker B.R., Nicholson G.C., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006, 174:753-762.
Wenzel S.E., Barnes P.J., Bleecker E.R., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
Holgate S.T., Noonan M., Chanez P., et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011, 37:1352-1359.
Simpson J.L., Powell H., Boyle M.J., et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
Louis R., Djukanovic R. Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease?. Clin Exp Allergy 2006, 36:563-567.
Keatings V.M., Barnes P.J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997, 155:449-453.
Moermans C., Heinen V., Nguyen M., et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine 2011, 56:298-304.
Albert R.K., Connett J., Bailey W.C., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
Martinez F.J., Curtis J.L., Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:331-350.
Barnes P.J. New therapies for asthma: is there any progress?. Trends Pharmacol Sci 2010, 31:335-343.
Cox G., Thomson N.C., Rubin A.S., et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007, 356:1327-1337.
Cox G. Bronchial thermoplasty for severe asthma. Curr Opin Pulm Med 2011, 17:34-38.
Pavord I.D., Cox G., Thomson N.C., et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007, 176:1185-1191.
Castro M., Rubin A.S., Laviolette M., et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010, 181:116-124.
Louis R., Sele J., Henket M., et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002, 57:907-912.
Gibson P.G., Simpson J.L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329-1336.
Simpson J.L., Scott R., Boyle M.J., et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006, 11:54-61.
Green R.H., Brightling C.E., Woltmann G., et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-879.
Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372:1107-1119.
Douwes J., Gibson P., Pekkanen J., et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002, 57:643-648.
Kharitonov S.A., Yates D., Robbins R.A., et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994, 343:133-135.
Berry M.A., Shaw D.E., Green R.H., et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175-1179.
Schleich F.N., Seidel L., Sele J., et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010, 65:1039-1044.
Szefler S.J., Martin R.J., King T.S., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 109:410-418.
Berry M., Morgan A., Shaw D.E., et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007, 62:1043-1049.
Cowan D.C., Cowan J.O., Palmay R., et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010, 65:384-390.
Meijer R.J., Postma D.S., Kauffman H.F., et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002, 32:1096-1103.
Pavord I.D., Brightling C.E., Woltmann G., et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999, 353:2213-2214.
Smith A.D., Cowan J.O., Brassett K.P., et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005, 172:453-459.
Woodruff P.G., Modrek B., Choy D.F., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009, 180:388-395.
Godon P., Boulet L.P., Malo J.L., et al. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002, 20:1364-1369.
Bacci E., Cianchetti S., Bartoli M., et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006, 129:565-572.
Culpitt S.V., Maziak W., Loukidis S., et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:1635-1639.
Keatings V.M., Jatakanon A., Worsdell Y.M., et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
Tantisira K.G., Lasky-Su J., Harada M., et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011, 365:1173-1183.
Cochrane M.G., Bala M.V., Downs K.E., et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000, 117:542-550.
Price D., Musgrave S.D., Shepstone L., et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011, 364:1695-1707.
Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595.
Louis R., Joos G., Michils A., et al. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009, 63:1479-1488.
Corren J., Lemanske R.F., Hanania N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
Balzar S., Fajt M.L., Comhair S.A., et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011, 183:299-309.
Pettipher R., Hansel T.T., Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007, 6:313-325.
Barnes P.J. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007, 119:1055-1062.

Similar publications